Abstract
The management of advanced genitourinary malignancies has undergone a major transformation with the advent of novel drugs and targeted therapies in recent years. Assessment of the treatment risks and benefits is required for each patient and therefore better knowledge of the different clinical and molecular aspects of these diseases is warranted. The results of further studies and biomarker validations are expected to provide more treatment options and improve outcomes in the future management of genitourinary malignancies.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis*
-
Clinical Trials as Topic
-
Disease-Free Survival
-
Drug Resistance, Neoplasm
-
Evidence-Based Medicine
-
Female
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Kidney Neoplasms / drug therapy
-
Male
-
Molecular Targeted Therapy* / methods
-
Orchiectomy
-
Prognosis
-
Prostatic Neoplasms / drug therapy
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Risk Factors
-
Treatment Outcome
-
Urinary Bladder Neoplasms / drug therapy
-
Urogenital Neoplasms / chemistry
-
Urogenital Neoplasms / drug therapy*
-
Vascular Endothelial Growth Factor A / drug effects
-
Vinblastine / analogs & derivatives
-
Vinblastine / therapeutic use
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Immunosuppressive Agents
-
Protein Kinase Inhibitors
-
Vascular Endothelial Growth Factor A
-
vinflunine
-
Vinblastine
-
Protein-Tyrosine Kinases